Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Vertex Pharmaceuticals Incorporated

5 clinical trials · 5 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Vertex Pharmaceuticals Incorporated

RECRUITINGPhase 3NCT04786262

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and...

Sponsor: Vertex Pharmaceuticals IncorporatedEnrolling: 5220 locations
Diabetes Mellitus, Type 1Impaired Hypoglycemic AwarenessSevere Hypoglycemia
RECRUITINGPhase 3NCT05422222

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at...

Sponsor: Vertex Pharmaceuticals IncorporatedEnrolling: 21020 locations
Cystic Fibrosis
RECRUITINGPhase 1NCT07283770

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.

Sponsor: Vertex Pharmaceuticals IncorporatedEnrolling: 1281 location
Cystic Fibrosis
RECRUITINGPhase 1NCT06154447

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/...

Sponsor: Vertex Pharmaceuticals IncorporatedEnrolling: 25511 locations
Cystic Fibrosis
RECRUITINGPhase 1 / Phase 2NCT05668741

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis...

Sponsor: Vertex Pharmaceuticals IncorporatedEnrolling: 3920 locations
Cystic Fibrosis